All Q2 FY26 results →

B

Biocon

Q2 FY26

Biocon Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹349

Market cap₹56.9K Cr

P/E78.3

Updated16 Oct 2026

Read5 min read

The short version

Biosimilars: Continued growth expected across all regions—North America (~40% of revenues), Europe (~35%), and Emerging Markets (~25%)—with market share gains in oncology products and insulin portfolio expansion. - Europe: Focus on increasing market presence, especially in oncology and immunology biosimilars, with additional product launches planned. - Emerging Markets: Aiming to self-lead in more countries and increase retail business balance to reduce dependence on tender processes. - Generics: Growth driven by new product launches in U.S. Biocon anticipates continued profitability improvement in upcoming quarters driven by structured debt settlements and margin expansions post-Goldman Sachs, Kotak, and Edelweiss exits.

From Biocon's Q2 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Biosimilars: Continued growth expected across all regions—North America (~40% of revenues), Europe (~35%), and Emerging Markets (~25%)—with market share gains in oncology products and insulin portfolio expansion.
Europe: Focus on increasing market presence, especially in oncology and immunology biosimilars, with additional product launches planned.
Emerging Markets: Aiming to self-lead in more countries and increase retail business balance to reduce dependence on tender processes.
Generics: Growth driven by new product launches in U.S. and EU, including Semaglutide filings globally; formulations expected to drive future growth.

2 more points from Biocon's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

Biocon anticipates continued profitability improvement in upcoming quarters driven by structured debt settlements and margin expansions post-Goldman Sachs, Kotak, and Edelweiss exits.
Full benefit of debt reduction reflected from FY '27 with annual interest cost savings of around INR 300 crores.
Biosimilars segment shows strong sequential revenue and EBITDA growth, sustaining EBITDA margin expansion to 25% in Q2 FY '26, signaling operating leverage benefits.
Generics business expected to strengthen further in H2 FY '26 with new product launches and broader market reach.
R&D investments steady around 7-9% of biosimilar revenues, supporting pipeline advancement without compromising margins.

2 more points from Biocon's call on margins

Pro opens every point from 15K+ earnings calls

See what Biocon said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The transcript does not explicitly mention specific current or future capex figures or detailed capital investments.
It notes capitalized new facilities impacting the Generics business margin, including three new facilities capitalized in FY '25, contributing to short-term margin pressures.
These new facilities include sites at Vizag, Cranbury, and a new peptide facility, which are ramping up and expected to drive growth.
Focus on expanding biosimilars and generics portfolios implies ongoing investments in R&D and commercial infrastructure.
R&D investments remain at 7-9% of biosimilars revenue and 8-10% of generics revenue, supporting pipeline development and new product launches.

2 more points from Biocon's call on capex

Pro opens every point from 15K+ earnings calls

Fundraising & Capital Structure

No specific mention of new fundraising through debt or equity in the current transcript.
The company has recently strengthened its balance sheet by settling structured debt obligations with Goldman Sachs and Kotak using QIP proceeds and has executed an agreement with Edelweiss.
Outstanding structured debt as of September 30th is only the Edelweiss instrument, with plans to exit by January 31st.
Short-term debt maturities mainly consist of revolving credit, which is not immediately payable.

2 more points from Biocon's call on fundraising

Pro opens every point from 15K+ earnings calls

See what Biocon said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided from the Biocon Q2 FY26 earnings call does not specifically mention details regarding the current or expected order book or pending orders. The discussion primarily focuses on: - Recent biosimilar product approvals and launches across geographies. - Market share gains and commercial traction in biosimilars, including insulin products. - Debt reduction and financial performance. - Strategic partnerships and government agreements for insulin supply.

2 more points from Biocon's call on order book

Pro opens every point from 15K+ earnings calls

Biocon — Quarterly revenue & net profit

Revenue Net profit Net loss

Dec 2024Q3 FY25

Mar 2025Q4 FY25

Jun 2025Q1 FY26

Sep 2025Q2 FY26

Dec 2025Q3 FY26

Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Biocon Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Bajaj Healthcare (Q2 FY26)
For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p
Infinium Pharma (Q2 FY26)
Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium
Wanbury (Q2 FY26)
Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against
Balaxi Pharma (Q2 FY26)
Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Biocon and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Biocon Q2 FY26 results?

Biosimilars: Continued growth expected across all regions—North America (~40% of revenues), Europe (~35%), and Emerging Markets (~25%)—with market share gains in oncology products and insulin portfolio expansion. - Europe: Focus on increasing market presence, especially in oncology and immunology biosimilars, with additional product launches planned. - Emerging Markets: Aiming to self-lead in more countries and increase retail business balance to reduce dependence on tender processes. - Generics: Growth driven by new product launches in U.S. Biocon anticipates continued profitability improvement in upcoming quarters driven by structured debt settlements and margin expansions post-Goldman Sachs, Kotak, and Edelweiss exits.

What is Biocon share price analysis?

Biocon currently shows a neutral. The stock trades at a P/E of 78.2 with a market cap of ₹56,909 Cr. Investors should review the full earnings analysis for detailed insights.

Is Biocon planning capital expenditure?

The transcript does not explicitly mention specific current or future capex figures or detailed capital investments.

Keep Biocon on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.